Reported Earlier, Trisalus Presented Additional Phase 1 Clinical Data During The Late-Breaker Oral Presentation Session At SITC 2023 Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Trisalus has presented additional Phase 1 clinical data during the Late-Breaker Oral Presentation Session at SITC 2023 Annual Meeting. The company's stock, TLSI, may be affected by this news.
November 06, 2023 | 6:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The presentation of additional Phase 1 clinical data by Trisalus at the SITC 2023 Annual Meeting may impact the company's stock, TLSI.
The presentation of additional Phase 1 clinical data is a significant event for Trisalus. This could potentially influence investor sentiment and impact the stock price of TLSI. However, the direction of the impact is uncertain without more specific information about the data presented.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100